Although BCL2 is frequently mutated in NHL,21, 22 these mutations do not affect sensitivity to ABT-737(ref. 22) and are unlikely to affect navitoclax or venetoclax efficacy. Here, BCL2 is linked to non-Hodgkin lymphoma.